Emcure Pharma surges 10%, stock hits new high on strong outlook

Analysts at Jefferies remain positive on Emcure Pharma's near- to mid-term outlook, supported by multiple growth drivers and operating-leverage benefits.

MarketNews shows the headline and summary published by the outlet. The full article is on the publisher's website. (www.business-standard.com)